Renal Cell Carcinoma — Trials

Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 376
Recruiting: 193
Ph III recruiting: 14
Growth YoY: +2.5%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (276)

clinicaltrialsPublishedShowing 301–350 of 681 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03200717	Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ)	completed	Phase 2	62	Novartis PharmaceuticalsINDUSTRY	11	Aug 21, 2023	clinicaltrials
NCT03961698	Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3)	unknown	Phase 2	91	Infinity Pharmaceuticals, Inc.